An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura

• Published in: Expert review of hematology Vol. 16; no. 1; p. 17
• Main Authors: Gómez-Seguí, Inés, Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, de la Rubia Comos, Javier
• Format: Journal Article
• Language: English
• Published: England 02-01-2023
• Subjects: ADAMTS13 Protein - genetics; Autoantibodies; Blood Coagulation; Humans; Mutation; Purpura, Thrombotic Thrombocytopenic - etiology; Purpura, Thrombotic Thrombocytopenic - genetics; diagnosis; ADAMTS13; Immune thrombotic thrombocytopenic purpura; pathophysiology
• ISSN: 1747-4094
• DOI: 10.1080/17474086.2023.2159803

Severe ADAMTS13 deficiency defines thrombotic thrombocytopenic purpura (TTP). ADAMTS13 is responsible for VWF cleavage. In the absence of this enzyme, widespread thrombi formation occurs, causing microangiopathic anemia and thrombocytopenia and leading to ischemic organ injury. Understanding ADAMTS13 function is crucial to diagnose and manage TTP, both in the immune and hereditary forms.
The role of ADAMTS13 in coagulation homeostasis and the consequences of its deficiency are detailed. Other factors that modulate the consequences of ADAMTS13 deficiency are explained, such as complement system activation, genetic predisposition, or the presence of an inflammatory status. Clinical suspicion of TTP is crucial to start prompt treatment and avoid mortality and sequelae. Available techniques to diagnose this deficiency and detect autoantibodies or gene mutations are presented, as they have become faster and more available in recent years.
A better knowledge of TTP pathophysiology is leading to an improvement in diagnosis and follow-up, as well as a customized treatment in patients with TTP. This scenario is necessary to define the role of new targeted therapies already available or coming soon and the need to better diagnose and monitor at the molecular level the evolution of the disease.